



Cytopeutics together with Department of Haematology, Hospital **Ampang** are carrying out a clinical study with the following title:

Cytopeutics[®] Umbilical Cord Mesenchymal Stem Cells (Cyto-MSC) for Patients with Grade II - IV Acute Graft-Versus-Host Disease: A Phase I/II Clinical Study

(NMRR-17-1114-36047 (ISR))

We are currently looking for patients who satisfied the following main inclusion & exclusion criteria to voluntarily participate in this study. Main inclusion criteria are:

- > Patient age 16 and above,
- > Patient who has undergone an allogeneic haematopoietic stem cell transplantation (HSCT) and developed grade II-IV acute graft versus host disease (acute GVHD),

Exclusion criteria are:

- Patient who has enrolled in another clinical trial (investigational drug or stem cell related) or has completed the aforesaid within 3 months.
- Patient with HIV or syphilis or Hep B (HBV) or Hep C (HCV).
- Patient with creatinine clearance of ≤50mL/min or creatinine of ≥200µmol/L
- Patient had undergone or on immune-modulatory treatment
- > Patient with progressive underlying disease or not in complete remission at time of transplant.
- Patient has receive HSCT transplant for solid tumour illness.
- Patient with hypersensitivity to dimethyl sulfoxide (DMSO)
- Female patient who is pregnant, lactating or planning for pregnancy

If you have encountered patients who fulfilled the above criteria, please contact the following correspondence:

> Department of Haematology, Hospital Ampang 03-4289 6559

> > Thank you very much.